Eton Pharmaceuticals (ETON) said Friday that the US Patent and Trademark Office has granted a patent for the formulation of its ET-600 product candidate, a desmopressin oral solution being developed as potential treatment for diabetes insipidus.
The company said the patent expires in 2044 and is expected to be listed in the FDA's Orange Book once ET-600 is approved.
Eton said it has another patent application related to the ET-600 product that is currently under review.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.